Feraccru®
Our lead product, Feraccru®, is a novel oral treatment available via prescription for the treatment of Iron Deficiency with or without anaemia which has received marketing authorisation in the European Union and Switzerland. A New Drug Application (NDA) for Feraccru® was submitted to the US Food & Drug Administration (FDA) in September 2018 and the application has a PDUFA (Prescription Drug Users Fee Act) date of 27th July 2019.
Read more
